Abbreviations/Acronyms	Definition
aRCC	Advanced renal cell carcinoma
IO	Immunotherapy
IO–IO	Immunotherapy combination
IO–TKI	Immunotherapy–VEGFR tyrosine kinase inhibitor combination
IMDC	International Metastatic RCC Database Consortium
OS	Overall survival
ORR	Objective response rate
PFS	Progression-free survival
AEs	Adverse events
CR	Complete response
HR	Hazard ratio
LLN	Lower limit of normal
ULN	Upper limit of normal
NCCN	National Comprehensive Cancer Network
ESMO	European Society of Medical Oncology
PEMBRO–AXI	Pembrolizumab–axitinib
PEMBRO–LENVA	Pembrolizumab–lenvatinib
NIVO–CABO	Nivolumab–cabozantinib
PRISMA Statement	Preferred Reporting Items for Systematic Reviews and Meta-Analyses report
RCT	Randomized clinical trial
CTCAE	Common Terminology Criteria for Adverse Events version 4
ASCO	American Society of Clinical Oncology
ROB	Risk of bias
RECIST	Response Evaluation Criteria in Solid Tumors
IV	Intravenous
IQR	Interquartile range
N	Number of patients
TMB	Tumor mutational burden